FDA Issues Warning Letters on Marketing and Sale of OTC CBD Products

The FDA issued warning letters to two companies this month, alleging FD&C Act violations stemming from marketing new drugs without approval. Companies marketing CBD products should be careful not to market OTC drugs containing CBD.

The post FDA Issues Warning Letters on Marketing and Sale of OTC CBD Products appeared first on Cannabis Industry Journal.

Cannabis & Chemicals: Why Glove Sourcing is Vital

Focusing on quality in the cannabis industry doesn’t just mean quality in cannabis, it should also speak to the quality of your supplies, equipment and materials. In this case study, an FDA-compliant food grade glove was the cause of a cannabis product recall.

The post Cannabis & Chemicals: Why Glove Sourcing is Vital appeared first on Cannabis Industry Journal.

GMPs & Cannabis Manufacturing

Kathleen May, Founder of Triskele Quality Solutions, provides a roadmap to Good Manufacturing Practices (GMPs) compliance for manufacturers in the cannabis industry.

The post GMPs & Cannabis Manufacturing appeared first on Cannabis Industry Journal.

Jazz Pharmaceuticals to Acquire GW Pharma

In a press release published last week, the two companies announced they have entered an agreement for Jazz to acquire GW Pharma, the producer of the only FDA-approved CBD medication Epidiolex, for a total of $7.2 billion.

The post Jazz Pharmaceuticals to Acquire GW Pharma appeared first on Cannabis Industry Journal.